Showing 4761-4770 of 5957 results for "".
- SIFI and Bausch Health Russia Announce Strategic Commercial Partnershiphttps://modernod.com/news/sifi-and-bausch-health-russia-announce-strategic-commercial-partnership/2479213/Italian ophthalmic company SIFI announced it has entered into a strategic multi-year agreement with Bausch Health Russia to market its products treating ophthalmic disorders in Russia. Terms of the deal were not disclosed. Initial sales are expected in 2021, marketing 5 SIFI product
- EyeTech Digital Systems Releases the EyeOn Open Eye-Tracking Platformhttps://modernod.com/news/eyetech-digital-systems-releases-the-eyeon-open-eye-tracking-platform/2479214/EyeTech Digital Systems announced the release of its software ecosystem for the EyeOn family of eye-tracking tablets. Software-agnostic EyeOn devices support EyeTech’s applications as well as third-party applications, arming engineers and end users with the highest reliability and lowest in
- At-Home App Helps Patients Stay Engaged and Adherent to Vision Monitoring Remotelyhttps://modernod.com/news/at-home-app-helps-patients-stay-engaged-and-adherent-to-vision-monitoring-remotely/2479208/Novartis announced it has begun a US pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely. Recent changes to public health protocols, paired with a growing patient population and existing treatment burden, have placed an emphasis on vi
- First Pediatric Patient with Rare Genetic Eye Disease Dosed in Clinical Trialhttps://modernod.com/news/first-pediatric-patient-with-rare-genetic-eye-disease-dosed-in-clinical-trial/2479207/ProQR Therapeutics has announced the first pediatric clinical trial participant has been treated in its new clinical trial named Brighten of the experimental RNA therapy sepofarsen. Brighten is a clinical study for children under 8 years old with Leber congenital amaurosis (LCA) d
- CDC Endorses Use of Pfizer, BioNTech COVID-19 Vaccine in Teens as Young as 12https://modernod.com/news/cdc-endorses-use-of-pfizer-biontech-covid-19-vaccine-in-teens-as-young-as-12/2479204/An advisory panel of the US Centers for Disease Control and Prevention (CDC) on Wednesday voted 14-0, with one recusal, to endorse the FDA’s recent decision to extend use of Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 to 12- to 15-year-olds, according to FirstWord. The recommendat
- Modernizing Medicine Releases Enhanced Ophthalmic Image Management to Improve Clinical Workflowhttps://modernod.com/news/modernizing-medicine-releases-enhanced-ophthalmic-image-management-to-improve-clinical-workflow/2479198/Modernizing Medicine announced it has released the latest version of ophthalmic Image Management aimed at helping ophthalmologists save time and deliver efficiency associated with diagnostic imaging workflows. Many ophthalmologists benefit from having an all-in-one solution that bridges da
- RVL Pharmaceuticals Upneeq Wins 2021 MedTech Breakthrough Awardhttps://modernod.com/news/rvl-pharmaceuticals-upneeq-wins-2021-medtech-breakthrough-award/2479196/RVL Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced that its ptosis drug Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of the “Best New Technology Solution for Drug Delivery” award in the fifth annual MedTech Breakthrough Award
- FDA Authorizes Pfizer, BioNTech’s COVID-19 Vaccine for Younger Adolescentshttps://modernod.com/news/fda-authorizes-pfizer-biontechs-covid-19-vaccine-for-younger-adolescents/2479191/The FDA on Monday expanded the emergency-use authorization (EUA) for Pfizer and BioNTech’s vaccine BNT162b2 to include preventing COVID-19 in adolescents 12 through 15 years of age, according to a FirstWord report. The two-dose mRNA-based vaccine was initially granted an EUA in December for
- Oculis Announces Positive Data From Two Proof-of-Concept Phase 2 Trials With OCS-02 in Dry Eye Disease and Acute Anterior Uveitishttps://modernod.com/news/oculis-announces-positive-data-from-two-proof-of-concept-phase-2-trials-with-ocs-02-in-dry-eye-disease-and-acute-anterior-uveitis/2479192/Oculis announced positive data from two clinical proof of concept phase 2 trials with OCS-02, its novel, topical anti-TNF alpha antibody fragment candidate, in dry eye disease (DED) and acute anterior uveitis (AAU). The data were presented for the first time at ARVO 2021, the annual meeting of th
- Bio-Tissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Diagnose and Treat Mechanical Dry Eyehttps://modernod.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/Bio-Tissue announced today that it will present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT, hosted by Neel Desai, MD, who will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to